# Lilly buys a two-year-old biotech for up to $300M. Nobody knows if it works yet.

- slug: lilly-buys-a-two-year-old-biotech-for-up-to-300m-nobody-knows-if-it-works-yet
- date: 2026-04-14
- category: Biotech & Life Sciences

Lilly is paying up to $300M for a two-year-old Houston biotech with zero drugs in human trials. CrossBridge raised $27.6M. That is an 11x premium on a GLP-1 winner converting cash into an oncology bet before anyone knows if it works.

---